NEWTOWN, PA, June 30, 2015– BioClinica®, Inc., the world’s leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe. The state-of-the-art facilities will offer an array of clinical trial services including medical imaging, site training and support, and eClinical product lines to meet the growing need of European drug and medical device sponsors. BioClinica‘s clients include top pharmaceutical, biotechnology, and medical device companies as well as CRO partnerships in Europe and across the globe.
“Our new offices will serve as important hubs that enable efficient delivery of tailored resources to our European and Global clients” said John Hubbard, BioClinica’s CEO. “Infrastructure investments and the recruitment of local scientific, medical, and regulatory expertise highlights BioClinica’s firm commitment to supporting clinical drug development in Europe”.
Together, the London and Munich offices offer a combined space of 1,400 square metersto support clinical trial services across key therapeutic areas. With a focus on medical imaging, the European offices will showcase an advanced image analysis center for BioClinica’s extensive network of European radiologists and imaging specialists. “Our expansion will provide the resources needed for regional scientific and medical experts to assemble and deliver high quality central review of imaging data for multisite trials in Europe” said David Herron, BioClinica’s President of Medical Imaging, Cardiovascular Safety, and Molecular Markers.
BioClinica is holding an open house event for the London office on July 2nd for clients, sponsors, and partners in which members of the Executive Leadership team and representatives from BioClinica’s Medical Imaging and Biomarker, Site network and patient recruitment, and eClinical business segments will be on hand to discuss and demonstrate clinical trial capabilities.
BioClinica is poised to expand its eClinical division in Europe, delivering products and showcasing technologies that facilitate efficient drug development in the region. “Our newly expanded offices provide an interactive environment for training and demonstration of our eClinical technology suite” said Mukhtar Ahmed, President of eClinical Solutions.
The London office is located at 72 Hammersmith Road and the Munich office is located at Landsberger Strasse 290. BioClinica has plans for an Open House at the Munich office later this summer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.